The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted Nigerians to the circulation of a suspected counterfeit asthma medicine, warning that its use could lead to treatment failure and other serious health risks. According to NAFDAC, AstraZeneca informed the agency that the product closely resembles its registered asthma medicine, Pulmicort (Budesonide) Nebulising Suspension, and could mislead healthcare professionals and patients. Product traced to AnambraProviding details of the suspected counterfeit product, NAFDAC said it bears the batch number 25770416E, with a manufacturing date of June 2025 and an expiry date of May 2027. The agency added that the suspected counterfeit product is labelled as being manufactured by Legency Remedies PVT Ltd, located in Himachal Pradesh, India. NAFDAC said it has commenced an investigation to determine the source and distribution network of the suspected counterfeit medicine.